08:23 AM EST, 02/13/2025 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) reported Q4 non-GAAP net income Thursday of $0.06 per diluted share, swinging from a net loss of $0.77 per share a year earlier.

Analysts polled by FactSet expected a loss of $0.26 per share.

Revenue for the quarter ended Dec. 31 was $593.2 million, up from $439.7 million a year earlier.

Analysts surveyed by FactSet expected $582.6 million.

The company's shares were up 1.9% in recent Thursday premarket activity.